Signatera™ MRD testing for HNSCC patient management

Join Dr. Krzysztof Misiukiewicz, MD and Dr. Michael Krainock, MD, PhD on a live webinar where they will review and discuss the latest clinical data supporting the use of Signatera™ ctDNA molecular residual disease (MRD) testing in HNSCC treatment care.